The results showed that after stimulation by tumor cells and Obinutuzumab, PB-NK cells lost most of their CD16 expression, whereas NK cells expressing hnCD16 and hnCD16FR could remain CD16 expression at high levels (Fig. 1D). The gene discussed is FCGR3A; the disease is neoplasm.